Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as an injectable solution for intravenous use. It enhances magnetic resonance imaging of the brain, central nervous system, liver and cardiovascular system in patients undergoing diagnostic imaging.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is used as a gadolinium‑based contrast agent to improve visualization in magnetic resonance imaging.

- Brain and central nervous system MRI: provides enhanced contrast to delineate lesions, tumors, and vascular structures. - Liver MRI: improves detection and characterization of focal liver lesions. - Cardiovascular MRI: enhances visualization of cardiac chambers, vessels, and perfusion.

Adverse reactions may occur after administration of Multihance.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Headache: transient discomfort following injection. - Injection site discomfort: pain or burning at the infusion site. - Warmth sensation: brief feeling of heat during administration. - Metallic taste: transient metallic sensation in the mouth. - Dizziness: mild vertigo or light‑headedness.

Serious or Rare Side Effects: - Allergic reactions: including anaphylaxis, urticaria, or bronchospasm. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: marked drop in blood pressure requiring medical intervention. - Cardiac arrest: rare but life‑threatening event. - Seizures: uncommon neurologic event.

Prior assessment and monitoring are essential when using Multihance.

- Renal function assessment: evaluate glomerular filtration rate before administration. - Pregnancy caution: safety not established; avoid unless clearly needed. - Breastfeeding consideration: advise caution as data are limited. - Prior allergic reactions: assess history of hypersensitivity to gadolinium agents. - Concomitant nephrotoxic drugs: use with caution when patients receive other renal‑impacting medications. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance may interact with other agents that affect renal function or hypersensitivity risk.

Major Interactions (Avoid): - Concurrent use of other gadolinium‑based contrast agents: increases cumulative gadolinium exposure. - High‑dose aminoglycoside antibiotics: may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: can alter renal clearance, requiring closer monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect kidney function. - ACE inhibitors or ARBs: may increase risk of renal impairment when combined with gadolinium agents.